Investigating how a protein complex affects the movement of RNA in advanced prostate cancer.
Function of the METTL3-NUP93 complex-mediated nuclear export of m6A-modified mRNAs in castration-resistant prostate cancer.
This study is looking at how a specific protein complex helps move important messages in cells related to castration-resistant prostate cancer, with the hope of finding new ways to improve treatment for patients dealing with this tough form of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-11251381 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a specific protein complex, METTL3-NUP93, in the movement of messenger RNAs (mRNAs) out of the nucleus in castration-resistant prostate cancer (CRPC). By examining how this complex interacts with cancer cells, the study aims to uncover the mechanisms that contribute to the progression of this aggressive form of prostate cancer. The researchers will utilize various laboratory techniques, including proteomic studies and immunohistochemistry, to analyze the expression and function of these proteins in cancer cells. The ultimate goal is to identify potential therapeutic targets that could improve treatment outcomes for patients with CRPC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with castration-resistant prostate cancer who are seeking new treatment options.
Not a fit: Patients with early-stage prostate cancer or those who do not have castration-resistant disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that specifically target the mechanisms driving advanced prostate cancer.
How similar studies have performed: While the specific interaction of the METTL3-NUP93 complex in prostate cancer is novel, similar approaches have shown promise in other cancer types, indicating potential for success.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Xu, Kexin — University of Virginia
- Study coordinator: Xu, Kexin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.